C
23.40
-0.85 (-3.51%)
| Penutupan Terdahulu | 24.25 |
| Buka | 24.15 |
| Jumlah Dagangan | 754,840 |
| Purata Dagangan (3B) | 1,224,169 |
| Modal Pasaran | 2,876,149,760 |
| Harga / Pendapatan (P/E TTM) | 13.93 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.97 |
| Harga / Jualan (P/S) | 5.24 |
| Harga / Buku (P/B) | 3.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | 36.91% |
| Margin Operasi (TTM) | 44.81% |
| EPS Cair (TTM) | 1.57 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 43.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 143.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.39% |
| Nisbah Semasa (MRQ) | 6.14 |
| Aliran Tunai Operasi (OCF TTM) | 267.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 223.08 M |
| Pulangan Atas Aset (ROA TTM) | 18.59% |
| Pulangan Atas Ekuiti (ROE TTM) | 29.11% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Catalyst Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.63 |
|
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 6.22% |
| % Dimiliki oleh Institusi | 83.18% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fundsmith Llp | 31 Dec 2025 | 3,363,807 |
| Julat 52 Minggu | ||
| Median | 35.00 (49.57%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 03 Mar 2026 | 35.00 (49.57%) | Beli | 23.92 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies |
| 05 Jan 2026 | Pengumuman | The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |